Article

European committee recommends approval of glaucoma treatment

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve bimatoprost/timolol ophthalmic solution (Ganfort, Allergan) for treatment of glaucoma.

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve bimatoprost/timolol ophthalmic solution (Ganfort, Allergan) for treatment of glaucoma.

CHMP’s opinion is the basis for the European Commission approval. Allergan expects final approval in the second quarter of 2006.

The combination drug’s indication is for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, plus insufficient responsiveness to topical beta-blockers or prostaglandin analogues.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.